| abstract |
Provided herein are Chimeric Antigen Receptors (CARs) for cancer therapy, more specifically, CARs comprising an scFv from an anti-MUC 16 monoclonal antibody. Immune effector cells comprising such CARs are provided, as well as methods of treating proliferative disorders. |